AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2024
Sep 16, 2024
62616_rns_2024-09-16_6f89b050-5539-4276-94a1-edb08eb87c08.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [144 x 47] intentionally omitted <==
September 16, 2024
BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR
Dear Madam/ Sir,
Sub: Press Release
Please find attached Press Release issued by the Company titled:
“Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths.”
Thanks & Regards,
For Strides Pharma Science Limited,
MANJULA Digitally signed by MANJULA R R Date: 2024.09.16 14:47:26 +05'30'
Manjula Ramamurthy Company Secretary ICSI Membership No. A30515
Encl. As above
==> picture [500 x 51] intentionally omitted <==
Press Release
September 16, 2024
==> picture [132 x 51] intentionally omitted <==
Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths
- Fluoxetine Tabs 60 mg approval solidifies the Company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Bangalore, India, September 16, 2024 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Fluoxetine Tabs 60 mg, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine Tablets, 60 mg, of TWi Pharmaceuticals, Inc.
With the approval of the Fluoxetine Tabs 60 mg strength, the Company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths. Fluoxetine Capsules and Tablets have a combined market size of ~US$ 130 Mn as per IMS.
The addition of the Fluoxetine Tabs 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The Company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry.
About Fluoxetine
Fluoxetine is an antidepressant of the Selective Serotonin Reuptake Inhibitor (SSRI) class. It is used for the treatment of Major Depressive Disorder (MDD), Obsessive–Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, with or without Agoraphobia.
About Strides
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.
For further information, please contact:
| Institutional Investors Vikesh Kumar Group CFO [email protected] Saurabh Ambaselkar Investor Relations +91 99609 31220 [email protected] Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 |
Corporate Communication Pallavi Panchmatia:+91 80 6784 0193 [email protected] PR Consultancy Adfactors PR Janhavi Bellare: +91 93228 54508 [email protected] Talal Syed:+91 99876 19679 [email protected] |
|
|---|---|---|